

# PÃ¼ivi Ã-stling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12138416/publications.pdf>

Version: 2024-02-01

21  
papers

1,550  
citations

516710

16  
h-index

713466

21  
g-index

21  
all docs

21  
docs citations

21  
times ranked

3130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening out irrelevant cell-based models of disease. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 751-769.	46.4	402
2	Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells. <i>Cancer Research</i> , 2011, 71, 1956-1967.	0.9	244
3	Heat Shock Factor 2 (HSF2) Contributes to Inducible Expression of hsp Genes through Interplay with HSF1. <i>Journal of Biological Chemistry</i> , 2007, 282, 7077-7086.	3.4	192
4	Role of heat-shock factor 2 in cerebral cortex formation and as a regulator of p35 expression. <i>Genes and Development</i> , 2006, 20, 836-847.	5.9	85
5	Consistency in drug response profiling. <i>Nature</i> , 2016, 540, E5-E6.	27.8	76
6	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327.	1.9	74
7	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , 2020, 36, 3602-3604.	4.1	68
8	Accurate Morphology Preserving Segmentation of Overlapping Cells based on Active Contours. <i>Scientific Reports</i> , 2016, 6, 32412.	3.3	60
9	Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. <i>European Urology</i> , 2016, 69, 1120-1128.	1.9	53
10	MicroRNA-135b regulates ER $\alpha$ , AR and HIF1AN and affects breast and prostate cancer cell growth. <i>Molecular Oncology</i> , 2015, 9, 1287-1300.	4.6	45
11	FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. <i>Cell Death and Differentiation</i> , 2019, 26, 2577-2593.	11.2	38
12	ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors. <i>Journal of Pathology</i> , 2020, 250, 159-169.	4.5	37
13	miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen. <i>European Urology</i> , 2015, 68, 581-588.	1.9	35
14	Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data. <i>Bioinformatics</i> , 2015, 31, 3815-3821.	4.1	31
15	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366.	5.1	29
16	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. <i>British Journal of Cancer</i> , 2019, 120, 435-443.	6.4	24
17	Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. <i>Nature Communications</i> , 2022, 13, 1691.	12.8	20
18	MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2021, 81, 5733-5744.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Application of precision medicine in clinical routine in haematologyâ€”Challenges and opportunities. Journal of Internal Medicine, 2022, 292, 243-261.	6.0	12
20	The transcriptomeâ€”wide landscape of molecular subtypeâ€”specific <scp>mRNA</scp> expression profiles in acute myeloid leukemia. American Journal of Hematology, 2021, 96, 580-588.	4.1	9
21	High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 4641-4641.	1.4	1